Biopharma LLC

Automation in the Global Biopharma Industry 2023-2033: Comprehensive Research Report with Global and Regional Revenue Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 29, 2023
Pharmaceutical, Health, Biometrics, Human, US, Automation, Risk, Clothing, Medical device, Fine chemical, Beauty salon, Sales, Biopharma LLC

The "Automation in Biopharma Industry Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Automation in Biopharma Industry Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • Biopharma automation can also reduce the risk of contamination by reducing the need for human intervention, thereby improving product purity.
  • Will leading automation in biopharma industry markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • Where is the automation in biopharma industry market heading and how can you ensure you are at the forefront of the market?

Spectrometry Industry Unlocks Growth Potentials in NMR Spectroscopy - Grand View Research, Inc.

Retrieved on: 
Wednesday, June 28, 2023
Food, GC/MS, IR, Ester, NMR, Mass spectrometry, Biotechnology, Biopharma LLC, Biomedical Research, Dicarboxylic acid, Research, Thermo Fisher Scientific, Near-infrared spectroscopy, USD, Proteomics, MS, Athlete, Nuclear magnetic resonance spectroscopy, Paint, Agilent Technologies, Acquisition, GC-MS, Investment, SAN, Drug discovery, Gas chromatography–mass spectrometry, Growth, Virtual Control, PCR, Red Data Book of Ukraine, Software, Fine chemical, Medical imaging

SAN FRANCISCO, June 28, 2023 /PRNewswire/ -- The global spectrometry industry size will witness robust growth on the back of growing applications across drug development procedures, forensic analysis and proteomics, according to the " Spectrometry Industry Data Book, 2023 - 2030 ," published by Grand View Research.

Key Points: 
  • SAN FRANCISCO, June 28, 2023 /PRNewswire/ -- The global spectrometry industry size will witness robust growth on the back of growing applications across drug development procedures, forensic analysis and proteomics, according to the " Spectrometry Industry Data Book, 2023 - 2030 ," published by Grand View Research.
  • Forward-looking players have upped investments in molecular spectrometry in pharmaceutical and biotechnology in the wake of innovation in infrared (IR) spectroscopy.
  • Equipment manufacturers have injected funds into mass spectrometry (MS) in the drug development pipeline, applied testing, clinical diagnostics and food products.
  • Order your copy of the Free Sample of "Spectrometry Industry Data Book - Spectrometry, Mass Spectrometry, NMR Spectroscopy, Near-Infrared Spectroscopy and In-line UV-vis Spectroscopy Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030" Data Book, published by Grand View Research
    An uptick in biomedical research has fueled the penetration of nuclear magnetic resonance (NMR) spectroscopy across business verticals.

Spectrometry Industry Unlocks Growth Potentials in NMR Spectroscopy - Grand View Research, Inc.

Retrieved on: 
Wednesday, June 28, 2023
Food, GC/MS, IR, Ester, NMR, Mass spectrometry, Biotechnology, Biopharma LLC, Biomedical Research, Dicarboxylic acid, Research, Thermo Fisher Scientific, Near-infrared spectroscopy, USD, Proteomics, MS, Athlete, Nuclear magnetic resonance spectroscopy, Paint, Agilent Technologies, Acquisition, GC-MS, Investment, SAN, Drug discovery, Gas chromatography–mass spectrometry, Growth, Virtual Control, PCR, Red Data Book of Ukraine, Software, Fine chemical, Medical imaging

SAN FRANCISCO, June 28, 2023 /PRNewswire/ -- The global spectrometry industry size will witness robust growth on the back of growing applications across drug development procedures, forensic analysis and proteomics, according to the " Spectrometry Industry Data Book, 2023 - 2030 ," published by Grand View Research.

Key Points: 
  • SAN FRANCISCO, June 28, 2023 /PRNewswire/ -- The global spectrometry industry size will witness robust growth on the back of growing applications across drug development procedures, forensic analysis and proteomics, according to the " Spectrometry Industry Data Book, 2023 - 2030 ," published by Grand View Research.
  • Forward-looking players have upped investments in molecular spectrometry in pharmaceutical and biotechnology in the wake of innovation in infrared (IR) spectroscopy.
  • Equipment manufacturers have injected funds into mass spectrometry (MS) in the drug development pipeline, applied testing, clinical diagnostics and food products.
  • Order your copy of the Free Sample of "Spectrometry Industry Data Book - Spectrometry, Mass Spectrometry, NMR Spectroscopy, Near-Infrared Spectroscopy and In-line UV-vis Spectroscopy Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030" Data Book, published by Grand View Research
    An uptick in biomedical research has fueled the penetration of nuclear magnetic resonance (NMR) spectroscopy across business verticals.

SpotSee Forms Life Science Advisory Council with Global Industry Leaders

Retrieved on: 
Tuesday, June 27, 2023
Software, Health, Packaging, Health Technology, Technology, Logistics, Supply Chain Management, Transport, Manufacturing, Clinical chemistry, GS1, HDA, McRoberts, Abbott, BD (company), Biopharma LLC, Doctor of Philosophy, Medical microbiology, PACT, Organization, IEEE, SITM, Thermo Fisher Scientific, National academy, CPHD, Capital, Stuart, MEMS, IVD, SAP, Growth, Johnson & Johnson, Cathcart, GTT, FDA, Management, Pharmaceutical industry, Pharma, Engineering, Qualcomm, Cepheid variable

SpotSee® , a global leader in supply chain indicators that protect products against damage and ensure supply chain integrity, has assembled its inaugural Life Science Advisory Council, bringing together a team of globally recognized experts.

Key Points: 
  • SpotSee® , a global leader in supply chain indicators that protect products against damage and ensure supply chain integrity, has assembled its inaugural Life Science Advisory Council, bringing together a team of globally recognized experts.
  • SpotSee's Life Science Advisory Council aims to utilize the combined expertise of its members to shape the company's product development, regulatory, and business strategies, thereby bolstering its industry success.
  • SpotSee will take advantage of the group's technical acumen, product development and innovation experience, as well as their industry networks, to accelerate growth in Life Sciences.
  • "We look forward to making SpotSee the premier provider of condition-monitoring solutions for organizations within the life science sector with the help of these carefully selected individuals."

PathAI Announces New Executive Appointment to Drive Commercial Growth of Biopharma Partnerships, Lab Capabilities, and Clinical Innovation

Retrieved on: 
Wednesday, June 14, 2023
PPD, Pathology, Medicine, Grow, Drug development, Thermo Fisher Scientific, Face, Patient, Marketing, Biopharma LLC, Management

BOSTON, June 14, 2023 /PRNewswire/ -- PathAI, a leading provider of AI-powered pathology tools to advance precision medicine, today announced that Matt Grow has joined as president of biopharma and chief business officer. The role will support PathAI's expanding biopharma commercial organization with a focus on the company's growing algorithm product suite and end-to-end clinical trial service offering for biopharma partners across all stages of drug development.

Key Points: 
  • The role will support PathAI's expanding biopharma commercial organization with a focus on the company's growing algorithm product suite and end-to-end clinical trial service offering for biopharma partners across all stages of drug development.
  • With more than 20 years of experience in biopharma business development, Grow brings a wealth of expertise to PathAI.
  • "We are thrilled to have Matt join the PathAI team as president of biopharma and chief business officer," said Andy Beck, M.D., Ph.D., chief executive officer and co-founder of PathAI.
  • "His deep expertise in biopharma business development and commercial operations will be instrumental in driving growth and building strategic partnerships.

Yseop Launches “Yseop Copilot,” the World’s Most Secure Digital Colleague for Scientific Writers

Retrieved on: 
Tuesday, June 6, 2023
Quality control, LLM Communications, Booth, GxP, LLM, Biopharma LLC, Automation, Generative, Medical device, Mobile phone, Synthetic media

Yseop Copilot supercharges productivity and keeps scientific writing in-house for quality control.

Key Points: 
  • Yseop Copilot supercharges productivity and keeps scientific writing in-house for quality control.
  • With Yseop Copilot, scientific writers across hundreds of clinical trials have slashed writing times and improved the consistency and reliability of reports in record time.
  • Yseop built this digital solution specifically for regulated industries like BioPharma, as proprietary prompts and validation methods ensure writing accuracy, while citations preserve traceability.
  • As leading pharmaceutical companies sprint to harness the impressive power of these tools, Yseop Copilot is empowering the future of scientific writing by creating the world’s most trusted digital colleague for automating scientific writing.

Ryan Stewart Joins MTS Health Partners

Retrieved on: 
Tuesday, June 6, 2023
WCAS, Partner, Research, Biopharma LLC, Sale, MTS, Warburg Pincus, Solomon Partners, Temasek, Leonard Green & Partners, Prime, CTI, Therapy, SVB Securities, Pharmaceutical industry, Pfizer

NEW YORK, June 6, 2023 /PRNewswire/ -- MTS Health Partners ("MTS"), a leading healthcare-dedicated investment bank that provides strategic and financial advice to the global healthcare industry, announced today that Ryan Stewart has joined the firm as a Partner in its New York office. As a key member of the MTS team, Ryan will work with Michael Ludwig to drive the firm's strategic initiatives in the rapidly evolving healthcare technology sector and expand the firm's industry-leading Healthcare Technology team.

Key Points: 
  • NEW YORK, June 6, 2023 /PRNewswire/ -- MTS Health Partners ("MTS"), a leading healthcare-dedicated investment bank that provides strategic and financial advice to the global healthcare industry, announced today that Ryan Stewart has joined the firm as a Partner in its New York office.
  • As a key member of the MTS team, Ryan will work with Michael Ludwig to drive the firm's strategic initiatives in the rapidly evolving healthcare technology sector and expand the firm's industry-leading Healthcare Technology team.
  • "We are thrilled to welcome Ryan to the MTS team," said Curtis Lane, Founding Partner of MTS.
  • "I am deeply honored to join MTS," said Ryan.

Thermo Fisher Scientific Showcases Solutions for Accelerating Biological Discovery

Retrieved on: 
Monday, June 5, 2023
Biotechnology, Technology, Other Health, Health, Pharmaceutical, Health Technology, Other Science, Medical Devices, Research, Software, Science, Astral, Vaccine, Data management, Maintenance, American Society for Mass Spectrometry, Therapy, ASMS, Mass spectrometry, George R. Brown Convention Center, Cancer, Chromatography, Chromatography software, Proteome, Web browser, Thermo Fisher Scientific, Biopharma LLC, Messenger, DDA, CDS, Protein, Acquisition, Algorithm, SP1, DIA, Society, Conference, Disease, Medical device, Computer data storage

Thermo Fisher Scientific is showcasing new mass spectrometry and chromatography instruments, software and workflows that enable customers to unlock deeper analytical insights, improve productivity and accelerate biological discovery.

Key Points: 
  • Thermo Fisher Scientific is showcasing new mass spectrometry and chromatography instruments, software and workflows that enable customers to unlock deeper analytical insights, improve productivity and accelerate biological discovery.
  • A seamless connection with the Thermo Scientific Ardia platform amplifies productivity and unlocks deeper insights into biotherapeutic characterization leading to safer biotherapies and vaccines.
  • New Thermo Scientific™ TraceFinder™ 5.2 SP1 software delivers innovative and flexible solutions for high throughput library screening and quantitation laboratories.
  • For more information on the Thermo Fisher solutions exhibited at ASMS 2023, please visit www.thermofisher.com/ASMS .

Hope for knee osteoarthritis sufferers with advent of global clinical trial.

Retrieved on: 
Wednesday, May 24, 2023
Paradigm, Osteoarthritis, Disease, Obesity, Depression, Hip, Life, Arthritis, Horse, Veterinarian, Anxiety, Biopharma LLC, Quality of life, Gamer, Pain, OA, Injury, Dog, Chemical oxygen demand, English Football League, Joint, Cat, Family, AFL, Knee, Pharmaceutical industry

MELBOURNE, Australia, May 24, 2023 /PRNewswire/ -- With the launch of a new website dedicated to their global clinical trials (https://hope4OA.com), Paradigm Biopharmaceuticals Ltd. (Paradigm Biopharma) aims to provide relief to millions of osteoarthritis (OA) sufferers worldwide by developing a new injectable drug.

Key Points: 
  • Due to their weight bearing role, 70% of all cases affect the hip or the knee.
  • Ex-Australian Football League (AFL) player Greg 'Diesel' Williams understands all too well how knee OA can have a devastating impact on your life.
  • Dr Philip Bloom comments "Osteoarthritis of the knee is not just an isolated pain in the knee.
  • Paradigm Biopharma aims to provide hope to OA sufferers by developing a drug to help relieve pain and improve symptoms in people with knee OA.

Celmatix Appoints Drug Development Expert Dr. Susan Herbert to Strategic Advisory Board

Retrieved on: 
Tuesday, May 16, 2023
Biotechnology, Pharmaceutical, Health, Other Health, Endometriosis, Business development, Venture, Drug development, Central Waqf Council, University, Senior, Doctor of Philosophy, Merck Group, Merck Serono, Biopharma LLC, Business, Woman, Advisory board, Federal Executive Boards, Inc., PCOS, Master of Science, Medicine, Corporation, United Kingdom, Knowledge, Growth, Merck, Pharmaceutical industry, Biochemistry

Celmatix Inc the leading women’s health biotech focused uniquely on ovarian biology, today announced that Dr. Susan Herbert has joined the company’s board of advisors.

Key Points: 
  • Celmatix Inc the leading women’s health biotech focused uniquely on ovarian biology, today announced that Dr. Susan Herbert has joined the company’s board of advisors.
  • Dr. Herbert brings more than 30 years of biopharma industry experience within R&D, business development and Corporate strategy along with unique insights gained heading the investment committee of MVentures.
  • Dr. Piraye Yurttas Beim, Celmatix Founder and CEO commented, “We are honored to have someone with Dr. Herbert’s experience and success in biopharma join our Strategic Advisory Board.
  • There has never been more at stake for women’s health and we are at the cusp of a new era in drug development.